SK667886A3 - Substituted bridged diazabicycloalkylquinolonecarboxylic acids, process for producing and pharmaceutical compositions containing the same - Google Patents
Substituted bridged diazabicycloalkylquinolonecarboxylic acids, process for producing and pharmaceutical compositions containing the same Download PDFInfo
- Publication number
- SK667886A3 SK667886A3 SK6678-86A SK667886A SK667886A3 SK 667886 A3 SK667886 A3 SK 667886A3 SK 667886 A SK667886 A SK 667886A SK 667886 A3 SK667886 A3 SK 667886A3
- Authority
- SK
- Slovakia
- Prior art keywords
- hinf
- formula
- diazabicyclo
- saur
- ecol
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 29
- 239000002253 acid Substances 0.000 title claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 8
- 150000007513 acids Chemical class 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 76
- -1 methoxy, N-methylamino, p-fluorophenyl Chemical group 0.000 claims abstract description 23
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims abstract description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 14
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 10
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 9
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 7
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 6
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims abstract description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 4
- 150000001768 cations Chemical class 0.000 claims abstract description 4
- 239000001257 hydrogen Substances 0.000 claims abstract description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims abstract description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 239000007858 starting material Substances 0.000 claims description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 150000001735 carboxylic acids Chemical class 0.000 claims description 6
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 5
- 150000001721 carbon Chemical group 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract description 10
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 7
- 229920002554 vinyl polymer Chemical group 0.000 abstract description 5
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 abstract 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 82
- 241001077878 Neurolaena lobata Species 0.000 description 79
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 40
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 28
- 239000007787 solid Substances 0.000 description 25
- 239000000203 mixture Substances 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 23
- 239000000047 product Substances 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 239000000243 solution Substances 0.000 description 19
- 102100031237 Cystatin-A Human genes 0.000 description 18
- 101000921786 Homo sapiens Cystatin-A Proteins 0.000 description 18
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
- 239000010410 layer Substances 0.000 description 14
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- FTTATHOUSOIFOQ-UHFFFAOYSA-N 1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazine Chemical compound C1NCCN2CCCC21 FTTATHOUSOIFOQ-UHFFFAOYSA-N 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 229910052938 sodium sulfate Inorganic materials 0.000 description 11
- 235000011152 sodium sulphate Nutrition 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- 238000002844 melting Methods 0.000 description 9
- 230000008018 melting Effects 0.000 description 9
- XJKNACDCUAFDHD-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.2]nonane Chemical compound C1CC2CCN1CCN2 XJKNACDCUAFDHD-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 239000000155 melt Substances 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 7
- MHFJYVWFBPABTI-UHFFFAOYSA-N 1-ethyl-6,7-difluoro-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(F)C=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHFJYVWFBPABTI-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 239000002026 chloroform extract Substances 0.000 description 6
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 5
- XNZIHVKLRKGFBS-UHFFFAOYSA-N 8-methyl-3,8-diazabicyclo[3.2.1]octane;dihydrochloride Chemical compound Cl.Cl.C1NCC2CCC1N2C XNZIHVKLRKGFBS-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- KNEXGVPHPGXAGF-UHFFFAOYSA-N 1-cyclopropyl-6,7-difluoro-4-oxoquinoline-3-carboxylic acid Chemical compound C12=CC(F)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 KNEXGVPHPGXAGF-UHFFFAOYSA-N 0.000 description 4
- YCAZALSUJDPQPP-UHFFFAOYSA-N 4-oxo-3h-quinoline-3-carboxylic acid Chemical compound C1=CC=C2C(=O)C(C(=O)O)C=NC2=C1 YCAZALSUJDPQPP-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- ZCYXXKJEDCHMGH-UHFFFAOYSA-N nonane Chemical compound CCCC[CH]CCCC ZCYXXKJEDCHMGH-UHFFFAOYSA-N 0.000 description 4
- BKIMMITUMNQMOS-UHFFFAOYSA-N normal nonane Natural products CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 150000003254 radicals Chemical group 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- PIDOCGDMKRSJMT-RSLHMRQOSA-N (1s,4s)-2,5-diazabicyclo[2.2.1]heptane;dihydrochloride Chemical compound Cl.Cl.C1N[C@@H]2CN[C@H]1C2 PIDOCGDMKRSJMT-RSLHMRQOSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- UXAWXZDXVOYLII-UHFFFAOYSA-N tert-butyl 2,5-diazabicyclo[2.2.1]heptane-2-carboxylate Chemical compound C1C2N(C(=O)OC(C)(C)C)CC1NC2 UXAWXZDXVOYLII-UHFFFAOYSA-N 0.000 description 3
- ZNZXELIYKDHAJA-UHFFFAOYSA-N 1-ethyl-6-fluoro-7-(8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)-4-oxoquinoline-3-carboxylic acid Chemical compound C1C(N2C)CCC2CN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(CC)C2=C1 ZNZXELIYKDHAJA-UHFFFAOYSA-N 0.000 description 2
- DHJRWNMTTJCQGO-UHFFFAOYSA-N 6,7-difluoro-1-methyl-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(F)C=C2N(C)C=C(C(O)=O)C(=O)C2=C1 DHJRWNMTTJCQGO-UHFFFAOYSA-N 0.000 description 2
- IVSHGBHPPSHNCA-UHFFFAOYSA-N 6-fluoro-1-(2-fluoroethyl)-7-(8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)-4-oxoquinoline-3-carboxylic acid Chemical compound FCCN1C=C(C(O)=O)C(=O)C(C=C2F)=C1C=C2N(C1)CC2CCC1N2C IVSHGBHPPSHNCA-UHFFFAOYSA-N 0.000 description 2
- OXURVGFLFRPDCF-UHFFFAOYSA-N 7-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-1-ethyl-6,8-difluoro-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN2CCC1CC2 OXURVGFLFRPDCF-UHFFFAOYSA-N 0.000 description 2
- PJYFVHIXGYHIGD-UHFFFAOYSA-N 7-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6,8-difluoro-1-(2-fluoroethyl)-4-oxoquinoline-3-carboxylic acid Chemical compound FC=1C=C2C(=O)C(C(=O)O)=CN(CCF)C2=C(F)C=1N1CCN2CCC1CC2 PJYFVHIXGYHIGD-UHFFFAOYSA-N 0.000 description 2
- ZHFGWIOLVRSZNQ-UHFFFAOYSA-N 8-chloro-1-cyclopropyl-6,7-difluoro-4-oxoquinoline-3-carboxylic acid Chemical compound C12=C(Cl)C(F)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 ZHFGWIOLVRSZNQ-UHFFFAOYSA-N 0.000 description 2
- NRCDIJJTFDJACX-UHFFFAOYSA-N 9-methyl-4,9-diazabicyclo[4.2.1]nonane Chemical compound C1CNCC2CCC1N2C NRCDIJJTFDJACX-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000006286 aqueous extract Substances 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 2
- KIMVTSGNCBGHES-UHFFFAOYSA-N octane;dihydrochloride Chemical compound Cl.Cl.CCCCCCCC KIMVTSGNCBGHES-UHFFFAOYSA-N 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- DJXNJVFEFSWHLY-UHFFFAOYSA-N quinoline-3-carboxylic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CN=C21 DJXNJVFEFSWHLY-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- CPKLWCPJBAELNP-USPAICOZSA-N (1s,4s)-2-methyl-2,5-diazabicyclo[2.2.1]heptane;dihydrochloride Chemical compound Cl.Cl.C1N(C)[C@]2([H])CN[C@@]1([H])C2 CPKLWCPJBAELNP-USPAICOZSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- ZLZISLYKANBVNC-WLHGVMLRSA-N (e)-but-2-enedioic acid;nonane Chemical compound OC(=O)\C=C\C(O)=O.CCCCCCCCC ZLZISLYKANBVNC-WLHGVMLRSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- VCIKVHACZDLJCT-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.2]nonan-3-one Chemical compound N1C(=O)CN2CCC1CC2 VCIKVHACZDLJCT-UHFFFAOYSA-N 0.000 description 1
- DTYLXDLAOLOTKT-UHFFFAOYSA-N 1,4-dihydroquinoline-3-carboxylic acid Chemical compound C1=CC=C2CC(C(=O)O)=CNC2=C1 DTYLXDLAOLOTKT-UHFFFAOYSA-N 0.000 description 1
- SYNRLLUJZOUMQL-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-2-one;hydrochloride Chemical compound Cl.C1CN2C(=O)CC1CC2 SYNRLLUJZOUMQL-UHFFFAOYSA-N 0.000 description 1
- ALRZZABRVIYCNY-BETUJISGSA-N 1-cyclopropyl-6-fluoro-7-[(1s,5r)-8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl]-4-oxoquinoline-3-carboxylic acid Chemical compound C([C@H]1CC[C@@H](C2)N1C)N2C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=CC=1N2C1CC1 ALRZZABRVIYCNY-BETUJISGSA-N 0.000 description 1
- CHAMGYZQVLLZHI-UHFFFAOYSA-N 1-cyclopropyl-7-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-fluoro-4-oxoquinoline-3-carboxylic acid Chemical compound C12=CC(N3C4CCN(CC4)CC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 CHAMGYZQVLLZHI-UHFFFAOYSA-N 0.000 description 1
- HEYIOFYFCUOKDL-UHFFFAOYSA-N 1-ethenyl-6,7-difluoro-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(F)C=C2C(=O)C(C(=O)O)=CN(C=C)C2=C1 HEYIOFYFCUOKDL-UHFFFAOYSA-N 0.000 description 1
- MZXJFGRQQQDFKM-UHFFFAOYSA-N 1-ethenyl-6-fluoro-7-(8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)-4-oxoquinoline-3-carboxylic acid Chemical compound C=CN1C=C(C(O)=O)C(=O)C(C=C2F)=C1C=C2N(C1)CC2CCC1N2C MZXJFGRQQQDFKM-UHFFFAOYSA-N 0.000 description 1
- FKKUVCHFRDLBHN-UHFFFAOYSA-N 1-ethyl-6,7,8-trifluoro-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(F)C(F)=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 FKKUVCHFRDLBHN-UHFFFAOYSA-N 0.000 description 1
- PZLPUVYSLZYCNH-UHFFFAOYSA-N 1-ethyl-6,8-difluoro-7-(8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)-4-oxoquinoline-3-carboxylic acid Chemical compound C1C(N2C)CCC2CN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(CC)C2=C1F PZLPUVYSLZYCNH-UHFFFAOYSA-N 0.000 description 1
- QPDAZRIQETWYHI-UHFFFAOYSA-N 1-methyl-3,8-diazabicyclo[3.2.1]octane dihydrochloride Chemical compound Cl.Cl.CC12CNCC(CC1)N2 QPDAZRIQETWYHI-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- ZMDQWHCTODNNLT-UHFFFAOYSA-N 2h-1,2-benzoxazine-3-carboxylic acid Chemical class C1=CC=C2ONC(C(=O)O)=CC2=C1 ZMDQWHCTODNNLT-UHFFFAOYSA-N 0.000 description 1
- QQZDECZROKFYDQ-UHFFFAOYSA-N 3,8-diazabicyclo[3.2.1]octane;dihydrochloride Chemical compound Cl.Cl.C1NCC2CCC1N2 QQZDECZROKFYDQ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- XQJMXPAEFMWDOZ-UHFFFAOYSA-N 3exo-benzoyloxy-tropane Natural products CN1C(C2)CCC1CC2OC(=O)C1=CC=CC=C1 XQJMXPAEFMWDOZ-UHFFFAOYSA-N 0.000 description 1
- NLRPLOMLCUJBET-UHFFFAOYSA-N 4-methyl-4,9-diazabicyclo[4.2.1]nonane Chemical compound C1N(C)CCC2CCC1N2 NLRPLOMLCUJBET-UHFFFAOYSA-N 0.000 description 1
- PZPBLDGLXNWULB-UHFFFAOYSA-N 6,7,8-trifluoro-1-(1-fluoroethyl)-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(F)C(F)=C2N(C(F)C)C=C(C(O)=O)C(=O)C2=C1 PZPBLDGLXNWULB-UHFFFAOYSA-N 0.000 description 1
- KRBQJNAQTNYREQ-UHFFFAOYSA-N 6,7,8-trifluoro-1-(2-fluoroethyl)-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(F)C=C2C(=O)C(C(=O)O)=CN(CCF)C2=C1F KRBQJNAQTNYREQ-UHFFFAOYSA-N 0.000 description 1
- ZBGVFPLTIBCTRU-UHFFFAOYSA-N 6,7-difluoro-1-(2-fluoroethyl)-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(F)C=C2C(=O)C(C(=O)O)=CN(CCF)C2=C1 ZBGVFPLTIBCTRU-UHFFFAOYSA-N 0.000 description 1
- BIZLICKRCDETKA-UHFFFAOYSA-N 6-fluoro-1-(2-fluoroethyl)-7-(9-methyl-4,9-diazabicyclo[4.2.1]nonan-4-yl)-4-oxoquinoline-3-carboxylic acid Chemical compound C1CC(C2)N(C)C1CCN2C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2CCF BIZLICKRCDETKA-UHFFFAOYSA-N 0.000 description 1
- PZVYAIIEIVMFHO-UHFFFAOYSA-N 6-fluoro-1-(4-fluorophenyl)-7-(8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)-4-oxoquinoline-3-carboxylic acid Chemical compound CN1C(C2)CCC1CN2C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=CC=1N2C1=CC=C(F)C=C1 PZVYAIIEIVMFHO-UHFFFAOYSA-N 0.000 description 1
- IYSFFCMYORSLNB-UHFFFAOYSA-N 6-fluoro-1-methyl-7-(8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)-4-oxoquinoline-3-carboxylic acid Chemical compound CN1C=C(C(O)=O)C(=O)C(C=C2F)=C1C=C2N(C1)CC2CCC1N2C IYSFFCMYORSLNB-UHFFFAOYSA-N 0.000 description 1
- UBGCCYGMLOBJOJ-UHFFFAOYSA-N 7-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-1-ethyl-6-fluoro-4-oxoquinoline-3-carboxylic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN2CCC1CC2 UBGCCYGMLOBJOJ-UHFFFAOYSA-N 0.000 description 1
- QPRZPTIWPFZPEH-UHFFFAOYSA-N 7-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-fluoro-1-(4-fluorophenyl)-4-oxoquinoline-3-carboxylic acid Chemical compound C12=CC(N3C4CCN(CC4)CC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1=CC=C(F)C=C1 QPRZPTIWPFZPEH-UHFFFAOYSA-N 0.000 description 1
- FKTYNDUTDZWGMO-UHFFFAOYSA-N 7-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-fluoro-1-(methylamino)-4-oxoquinoline-3-carboxylic acid Chemical compound C1=C2N(NC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN2CCC1CC2 FKTYNDUTDZWGMO-UHFFFAOYSA-N 0.000 description 1
- ALBSHLLFKPNOJO-UHFFFAOYSA-N 7-(9-benzyl-4,9-diazabicyclo[4.2.1]nonan-4-yl)-1-ethyl-6-fluoro-4-oxoquinoline-3-carboxylic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N(C1)CCC2CCC1N2CC1=CC=CC=C1 ALBSHLLFKPNOJO-UHFFFAOYSA-N 0.000 description 1
- BVMNCVGZGHZACI-UWVGGRQHSA-N 7-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-1-ethyl-6-fluoro-4-oxoquinoline-3-carboxylic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1[C@H](CN2)C[C@H]2C1 BVMNCVGZGHZACI-UWVGGRQHSA-N 0.000 description 1
- LHZDPJRHQVYKPA-ONGXEEELSA-N 7-[(1s,4s)-2-aza-5-azoniabicyclo[2.2.1]heptan-2-yl]-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylate Chemical compound C([C@]1(NC[C@]2([H])C1)[H])N2C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=CC=1N2C1CC1 LHZDPJRHQVYKPA-ONGXEEELSA-N 0.000 description 1
- VFOKZJNICLTVKA-UHFFFAOYSA-N 7-fluoro-2-methyl-6-(8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C(C)CO3)=O)=C2C3=C1N1CC(N2C)CCC2C1 VFOKZJNICLTVKA-UHFFFAOYSA-N 0.000 description 1
- OEQLRNPJISMKHT-UHFFFAOYSA-N 7-methyl-4-oxo-3h-1,8-naphthyridine-3-carboxylic acid Chemical compound O=C1C(C(O)=O)C=NC2=NC(C)=CC=C21 OEQLRNPJISMKHT-UHFFFAOYSA-N 0.000 description 1
- IKLWKDLOEJUBQB-QWRGUYRKSA-N 8-chloro-1-cyclopropyl-6-fluoro-7-[(1s,4s)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]-4-oxoquinoline-3-carboxylic acid Chemical compound C([C@@H]1C[C@H]2CN1C)N2C(C=1Cl)=C(F)C=C(C(C(C(O)=O)=C2)=O)C=1N2C1CC1 IKLWKDLOEJUBQB-QWRGUYRKSA-N 0.000 description 1
- ZXQURXQKPABSJY-UHFFFAOYSA-N 8-methyl-4,9-diazabicyclo[4.2.1]nonane Chemical compound C1NCCC2C(C)CC1N2 ZXQURXQKPABSJY-UHFFFAOYSA-N 0.000 description 1
- JRLTTZUODKEYDH-UHFFFAOYSA-N 8-methylquinoline Chemical group C1=CN=C2C(C)=CC=CC2=C1 JRLTTZUODKEYDH-UHFFFAOYSA-N 0.000 description 1
- WJNTXJZFBOWQPF-UHFFFAOYSA-N 9-benzyl-4,9-diazabicyclo[4.2.1]nonane Chemical compound C1NCCC2CCC1N2CC1=CC=CC=C1 WJNTXJZFBOWQPF-UHFFFAOYSA-N 0.000 description 1
- ZPLMTUXXQQUKDH-UHFFFAOYSA-N 9-methyl-4,9-diazabicyclo[4.2.1]nonan-3-one Chemical compound C1NC(=O)CC2CCC1N2C ZPLMTUXXQQUKDH-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- ZHSBCYSABQTFQD-IRXDYDNUSA-N C(C)N1C=C(C(C2=CC(=C(C=C12)N1[C@@H]2CN([C@H](C1)C2)CC2=CC=CC=C2)F)=O)C(=O)O Chemical compound C(C)N1C=C(C(C2=CC(=C(C=C12)N1[C@@H]2CN([C@H](C1)C2)CC2=CC=CC=C2)F)=O)C(=O)O ZHSBCYSABQTFQD-IRXDYDNUSA-N 0.000 description 1
- IOEGBPUYOICZJC-UHFFFAOYSA-N C(C)N1CC(C(C2=CC(=C(C=C12)N1C2CNC(C1)C2)F)=O)C(=O)O Chemical compound C(C)N1CC(C(C2=CC(=C(C=C12)N1C2CNC(C1)C2)F)=O)C(=O)O IOEGBPUYOICZJC-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LHTQDTMHCMHYPJ-UHFFFAOYSA-N FC(C)N1C=C(C(C2=CC(=C(C(=C12)F)C1C2CCC(CN1)N2C)F)=O)C(=O)O Chemical compound FC(C)N1C=C(C(C2=CC(=C(C(=C12)F)C1C2CCC(CN1)N2C)F)=O)C(=O)O LHTQDTMHCMHYPJ-UHFFFAOYSA-N 0.000 description 1
- SRJFTNIDWMHBOB-UHFFFAOYSA-N FC=1C=C2C(C=C(N(C2=CC1F)C1=CC=C(C=C1)F)C(=O)O)=O Chemical compound FC=1C=C2C(C=C(N(C2=CC1F)C1=CC=C(C=C1)F)C(=O)O)=O SRJFTNIDWMHBOB-UHFFFAOYSA-N 0.000 description 1
- YZTAVKRNABVWMU-UHFFFAOYSA-N FC=1C=C2C(C=C(N(C2=CC1F)C=C)C(=O)O)=O Chemical compound FC=1C=C2C(C=C(N(C2=CC1F)C=C)C(=O)O)=O YZTAVKRNABVWMU-UHFFFAOYSA-N 0.000 description 1
- KWZMMUWNXKSPIM-UHFFFAOYSA-N FC=1C=C2C(C=C(N(C2=CC1F)CCF)C(=O)O)=O Chemical compound FC=1C=C2C(C=C(N(C2=CC1F)CCF)C(=O)O)=O KWZMMUWNXKSPIM-UHFFFAOYSA-N 0.000 description 1
- KAICUEPFSOTPCV-UHFFFAOYSA-N FC=1C=C2C(C=C(N(C2=CC1F)NC)C(=O)O)=O Chemical compound FC=1C=C2C(C=C(N(C2=CC1F)NC)C(=O)O)=O KAICUEPFSOTPCV-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- 241000588749 Klebsiella oxytoca Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000588772 Morganella morganii Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- QQXLDOJGLXJCSE-UHFFFAOYSA-N N-methylnortropinone Natural products C1C(=O)CC2CCC1N2C QQXLDOJGLXJCSE-UHFFFAOYSA-N 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000588778 Providencia stuartii Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- QIZDQFOVGFDBKW-DHBOJHSNSA-N Pseudotropine Natural products OC1C[C@@H]2[N+](C)[C@H](C1)CC2 QIZDQFOVGFDBKW-DHBOJHSNSA-N 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940092559 enterobacter aerogenes Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- KGZLFTWMCMEEJR-UHFFFAOYSA-N heptane;hydrochloride Chemical compound Cl.CCCCCCC KGZLFTWMCMEEJR-UHFFFAOYSA-N 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 125000000687 hydroquinonyl group Chemical group C1(O)=C(C=C(O)C=C1)* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229940076266 morganella morganii Drugs 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- LOAUVZALPPNFOQ-UHFFFAOYSA-N quinaldic acid Chemical compound C1=CC=CC2=NC(C(=O)O)=CC=C21 LOAUVZALPPNFOQ-UHFFFAOYSA-N 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical group C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- XRXDAJYKGWNHTQ-UHFFFAOYSA-N quipazine Chemical class C1CNCCN1C1=CC=C(C=CC=C2)C2=N1 XRXDAJYKGWNHTQ-UHFFFAOYSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- CYHOMWAPJJPNMW-JIGDXULJSA-N tropine Chemical compound C1[C@@H](O)C[C@H]2CC[C@@H]1N2C CYHOMWAPJJPNMW-JIGDXULJSA-N 0.000 description 1
- JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Materials For Photolithography (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77747185A | 1985-09-18 | 1985-09-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK278605B6 SK278605B6 (en) | 1997-11-05 |
| SK667886A3 true SK667886A3 (en) | 1997-11-05 |
Family
ID=25110350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK6678-86A SK667886A3 (en) | 1985-09-18 | 1986-09-16 | Substituted bridged diazabicycloalkylquinolonecarboxylic acids, process for producing and pharmaceutical compositions containing the same |
Country Status (42)
| Country | Link |
|---|---|
| US (3) | US4775668A (zh) |
| EP (1) | EP0215650B1 (zh) |
| JP (1) | JPH0798819B2 (zh) |
| KR (1) | KR870000961B1 (zh) |
| CN (1) | CN1014789B (zh) |
| AT (1) | ATE72245T1 (zh) |
| AU (1) | AU576302B2 (zh) |
| BG (2) | BG49275A3 (zh) |
| CA (1) | CA1340734C (zh) |
| CY (1) | CY1774A (zh) |
| CZ (1) | CZ277825B6 (zh) |
| DD (1) | DD259190A5 (zh) |
| DE (2) | DE19675019I2 (zh) |
| DK (1) | DK171276B1 (zh) |
| EG (1) | EG18184A (zh) |
| ES (1) | ES2001428A6 (zh) |
| FI (1) | FI87565C (zh) |
| GR (1) | GR862363B (zh) |
| HK (1) | HK132795A (zh) |
| HU (1) | HU200462B (zh) |
| IE (1) | IE58966B1 (zh) |
| IL (1) | IL80033A (zh) |
| IN (1) | IN166416B (zh) |
| LU (1) | LU90356I2 (zh) |
| MA (1) | MA20770A1 (zh) |
| MW (1) | MW5886A1 (zh) |
| MX (1) | MX173358B (zh) |
| MY (1) | MY102518A (zh) |
| NO (1) | NO170335C (zh) |
| NZ (1) | NZ217614A (zh) |
| OA (1) | OA08410A (zh) |
| PH (2) | PH24048A (zh) |
| PL (1) | PL149987B1 (zh) |
| PT (1) | PT83388B (zh) |
| SG (1) | SG28094G (zh) |
| SK (1) | SK667886A3 (zh) |
| SU (1) | SU1482531A3 (zh) |
| UA (1) | UA6340A1 (zh) |
| YU (1) | YU45024B (zh) |
| ZA (1) | ZA867063B (zh) |
| ZM (1) | ZM8586A1 (zh) |
| ZW (1) | ZW19386A1 (zh) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN166416B (zh) * | 1985-09-18 | 1990-05-05 | Pfizer | |
| DE3601567A1 (de) * | 1986-01-21 | 1987-07-23 | Bayer Ag | 7-(azabicycloalkyl)-chinoloncarbonsaeure- und -naphthyridon-carbonsaeure-derivate |
| EP0251308B1 (de) * | 1986-07-04 | 1990-11-22 | Chemie Linz Gesellschaft m.b.H. | 4-Chinolon-3-carbonsäurederivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate |
| US4965273A (en) * | 1986-10-08 | 1990-10-23 | Bristol-Myers Company | Certain 1-tertiary-butyl-naphthyridone carboxylic acid derivatives anti-bacterial agents |
| WO1989000158A1 (en) * | 1987-07-02 | 1989-01-12 | Pfizer Inc. | Bridged-diazabicycloalkyl quinolone carboxylic acids and esters |
| US4923879A (en) * | 1987-07-31 | 1990-05-08 | Warner-Lambert Company | 1,8-Naphthyridines and their use as antibacterial agents |
| US4992546A (en) * | 1987-07-31 | 1991-02-12 | Warner-Lambert Company | Process for preparing 6,8-diazabicyclo[3.2.2]nonane derivatives |
| US4968799A (en) * | 1987-07-31 | 1990-11-06 | Warner-Lambert Company | Antibacterial agents |
| US4933335A (en) * | 1987-08-07 | 1990-06-12 | Warner-Lambert Company | Quinolones as antibacterial agents |
| WO1989005643A1 (en) * | 1987-12-18 | 1989-06-29 | Pfizer Inc. | Heterocyclic-substituted quinoline-carboxylic acids |
| DE3902079A1 (de) * | 1988-04-15 | 1989-10-26 | Bayer Ag | I.m. injektionsformen von gyrase-inhibitoren |
| US5147873A (en) * | 1988-08-23 | 1992-09-15 | Pfizer Inc. | Amino-substituted bridged azabicyclic quinolone carboxylic acids and esters |
| WO1990002123A1 (en) * | 1988-08-23 | 1990-03-08 | Pfizer Inc. | Amino-substituted bridged azabicyclic quinolone carboxylic acids and esters |
| US4895943A (en) * | 1988-10-25 | 1990-01-23 | Pfizer Inc. | Preparation of 1,4-diazabicyclo(3.2.2)nonane |
| US5036153A (en) * | 1989-05-11 | 1991-07-30 | Braish Tamim F | Preparation of 2,5-diazabicyclo[2.2.1]heptanes and intermediates |
| US5214051A (en) * | 1989-08-01 | 1993-05-25 | Pfizer Inc. | Thiazolyl and oxazolyl[5,4-c]piperidyl-substituted quinolone-carboxylic acid and related analogs thereof having antibacterial properties are disclosed |
| US5157125A (en) * | 1989-09-25 | 1992-10-20 | Pfizer Inc. | Optically active 2-alkyl-2,5-diazabicyclo[2.2.1]heptanes |
| US5013839A (en) * | 1989-09-25 | 1991-05-07 | Pfizer Inc. | Process for optically active 2-alkyl-2,5-diazabicyclo(2.2.1) heptanes |
| US5095121A (en) * | 1989-09-25 | 1992-03-10 | Pfizer Inc | Process for optically active 2-alkyl-2,5-diazabicyclo(2.2.1)heptanes |
| WO1991004972A1 (en) * | 1989-10-06 | 1991-04-18 | Pfizer Inc. | 1,4-dihydro-4-oxo-3-quinoline derivatives as selectively toxic mammalian antibacterial agents |
| US5385913A (en) * | 1989-10-06 | 1995-01-31 | Pfizer Inc. | 1,4-dihydro-4-oxo-3-quinoline derivatives as selectively toxic mammalian antibacterial agents |
| US4992449A (en) * | 1990-02-01 | 1991-02-12 | American Cyanamid Company | 7-(substituted)cycloalkylamino-1-(substituted)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids |
| US5580872A (en) * | 1990-05-02 | 1996-12-03 | Abbott Laboratories | Quinolizinone type compounds |
| DE69200921T2 (de) * | 1991-03-01 | 1995-05-04 | Pfizer | 1-azabicyclo[3.2.2]nonan-3-aminderivate. |
| US5235054A (en) * | 1992-07-15 | 1993-08-10 | Pfizer Inc. | 3-carboxaldehyde substituted quinolines and naphthyridines |
| GB2291421A (en) * | 1994-07-16 | 1996-01-24 | Pfizer | A process for preparing a quinoline carboxylic acid |
| ES2092963B1 (es) * | 1995-04-12 | 1997-12-16 | Sint Quimica Sa | Procedimiento para la preparacion del acido 1-ciclopropil-6-fluoro-1, 4-dihidro-7-(1s,4s)-5-metil-2,5-diazabiciclo(2.2.1) hept-2-il)-4-oxo-3-quinolincarboxilico y sus sales. |
| US5929086A (en) | 1996-05-10 | 1999-07-27 | Pharmacia & Upjohn Company | Topical administration of antimicrobial agents for the treatment of systemic bacterial diseases |
| US6056436A (en) * | 1997-02-20 | 2000-05-02 | University Of Maryland | Simultaneous measurement of temperature and strain using optical sensors |
| DE60008866T2 (de) | 1999-05-04 | 2005-01-27 | Neurosearch A/S | Heteroaryl diazabicycloalkene, deren herstellung und verwendung |
| FR2809731B1 (fr) * | 2000-05-31 | 2002-07-19 | Sanofi Synthelabo | Derives de 1,4-diazabicyclo-[3.2.2] nonane-pheylisoxazole, leur preparation et leur application en therapeutique |
| FR2809730B1 (fr) * | 2000-05-31 | 2002-07-19 | Sanofi Synthelabo | Derives de 1,4-diazabicyclo[3.2.2] nonanebenzoxazole, -benzothiazole et -benzimidazole, leur preparation et leur application therapeutique |
| FR2809732B1 (fr) * | 2000-05-31 | 2002-07-19 | Sanofi Synthelabo | DERIVES DE 4(-2-PHENYLTHIAZOL-5-yl)-1,4-DIAZABICYCLO-[3.2.2] NONANE, LEUR PREPARATION ET LEUR APPLICATION ENTHERAPEUTIQUE |
| DE60202667T2 (de) * | 2001-03-02 | 2005-06-16 | Neurosearch A/S | Neue 2,5-diazabicyclo [2.2.1] heptanderivate |
| EP1551843A1 (en) * | 2002-09-10 | 2005-07-13 | Pfizer Products Inc. | Diazabicyclic compounds useful in the treatment of cns and other disorders |
| KR101129933B1 (ko) * | 2002-09-25 | 2012-03-23 | 메모리 파마슈티칼스 코포레이션 | 인다졸, 벤조티아졸 및 벤조이소티아졸 및 그의 제조 및용도 |
| DE10312346A1 (de) * | 2003-03-20 | 2004-09-30 | Bayer Healthcare Ag | Kontrolliertes Freisetzungssystem |
| DE10351448A1 (de) | 2003-11-04 | 2005-06-09 | Bayer Healthcare Ag | Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften |
| PL1697378T3 (pl) * | 2003-12-22 | 2008-04-30 | Memory Pharm Corp | Indole, 1h-indazole, 1,2-benzoizoksazole i 1,2-benzoizotiazole oraz ich wytwarzanie i zastosowania |
| US20050234095A1 (en) | 2004-03-25 | 2005-10-20 | Wenge Xie | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof |
| ATE487716T1 (de) * | 2004-04-22 | 2010-11-15 | Memory Pharm Corp | Indole, 1h-indazole, 1,2-benzisoxazole, 1,2- benzoisothiazole, deren herstellung und verwendungen |
| NZ551712A (en) * | 2004-05-07 | 2010-07-30 | Memory Pharm Corp | 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparations and uses thereof |
| DE102005055385A1 (de) * | 2004-12-09 | 2006-06-14 | Bayer Healthcare Ag | Arzneimittel zur hygienischen Applikation im Ohr |
| CA2591817A1 (en) * | 2004-12-22 | 2006-06-29 | Memory Pharmaceuticals Corporation | Nicotinic alpha-7 receptor ligands and preparation and uses thereof |
| US8106066B2 (en) * | 2005-09-23 | 2012-01-31 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
| US7687517B2 (en) | 2006-02-10 | 2010-03-30 | Neurosearch A/S | 3,9-Diazabicyclo [3.3.1] nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| CA2641678A1 (en) | 2006-02-10 | 2007-08-16 | Neurosearch A/S | 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| WO2007090888A1 (en) | 2006-02-10 | 2007-08-16 | Neurosearch A/S | 3-heteroaryl- 3,9-diazabicyclo[3.3.1]nonane derivatives as nicotinic acetylcholine receptor agonists |
| DE102006010643A1 (de) | 2006-03-08 | 2007-09-13 | Bayer Healthcare Aktiengesellschaft | Arzneimittel enthaltend Fluorchinolone |
| DE102006010642A1 (de) * | 2006-03-08 | 2007-09-27 | Bayer Healthcare Aktiengesellschaft | Arzneimittelformulierungen, enthaltend Fluorchinolone |
| DE102007026550A1 (de) * | 2007-06-08 | 2008-12-11 | Bayer Healthcare Ag | Extrudate mit verbesserter Geschmacksmaskierung |
| DE102007055341A1 (de) | 2007-11-19 | 2009-05-20 | Bayer Animal Health Gmbh | Stabilisierung öliger Suspensionen enthaltend hydrophobe Kieselsäuren |
| WO2009111680A1 (en) * | 2008-03-07 | 2009-09-11 | Smithline Beecham Corporation | Trpv4 antagonists |
| WO2010104205A1 (en) * | 2009-03-11 | 2010-09-16 | Kyorin Pharmaceutical Co., Ltd. | 7-cycloalkylaminoquinolones as gsk-3 inhibitors |
| AU2011315555B2 (en) | 2010-10-12 | 2016-03-10 | Elanco Animal Health Gmbh | Non-starch based soft chewables |
| US10543170B2 (en) | 2012-12-19 | 2020-01-28 | Bayer Animal Health Gmbh | Tablets with improved acceptance and good storage stability |
| MD4291C1 (ro) * | 2013-12-27 | 2015-02-28 | Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова | Preparat medicamentos pentru tratamentul otitelor |
| CN114727622A (zh) * | 2019-09-06 | 2022-07-08 | 礼蓝美国公司 | 适口颗粒状兽用药组合物 |
| CN115368369A (zh) * | 2022-08-16 | 2022-11-22 | 浙江国邦药业有限公司 | 一种甲磺酸达氟沙星脱甲基杂质的合成方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS53141286A (en) * | 1977-05-16 | 1978-12-08 | Kyorin Seiyaku Kk | Novel substituted quinolinecarboxylic acid |
| CA1175836A (en) * | 1977-09-20 | 1984-10-09 | Marcel Pesson | Production of 1,4-dihydroquinoline-3-carboxylic acid derivatives |
| JPS54112876A (en) * | 1978-02-20 | 1979-09-04 | Sumitomo Chem Co Ltd | Preparation of 1-substituted-1,4-dihydro-4-oxo-3-quinoline carboxylic acid derivatives |
| JPS5845426B2 (ja) * | 1978-09-29 | 1983-10-08 | 杏林製薬株式会社 | 置換キノリンカルボン酸誘導体 |
| JPS5746986A (en) * | 1980-09-02 | 1982-03-17 | Dai Ichi Seiyaku Co Ltd | Pyrido(1,2,3-de)(1,4)benzoxazine derivative |
| JPS5823381A (ja) * | 1981-08-05 | 1983-02-12 | Nec Corp | 磁気バブル検出装置 |
| JPS5823382A (ja) * | 1981-08-05 | 1983-02-12 | Nec Corp | コンテイギユアス・デイスク・バブル検出・消去器 |
| JPS58204193A (ja) * | 1982-01-14 | 1983-11-28 | Kobe Steel Ltd | 表面処理鋼板 |
| US4499091A (en) * | 1982-03-31 | 1985-02-12 | Sterling Drug Inc. | 1-Amino (or substituted amino)-1,4-dihydro-4-oxo-6-fluoro-7-heterylquinoline-3-carboxylic acids and their use as antibacterial agents |
| EP0090424B1 (en) * | 1982-03-31 | 1986-05-28 | Sterling Drug Inc. | New quinolone compounds and preparation thereof |
| JPS58204194A (ja) * | 1982-05-21 | 1983-11-28 | Hitachi Ltd | 電気ニツケルメツキ方法 |
| JPS58219293A (ja) * | 1982-06-15 | 1983-12-20 | Chiyoda Chem Eng & Constr Co Ltd | 重質油の水素化分解方法 |
| US4665079A (en) * | 1984-02-17 | 1987-05-12 | Warner-Lambert Company | Antibacterial agents |
| IE55898B1 (en) * | 1982-09-09 | 1991-02-14 | Warner Lambert Co | Antibacterial agents |
| JPS59137481A (ja) * | 1983-01-26 | 1984-08-07 | Hokuriku Seiyaku Co Ltd | ７−ジアザビシクロアルカン置換−４−オキソ−１，４−ジヒドロキノリン−３−カルボン酸誘導体 |
| US4730000A (en) * | 1984-04-09 | 1988-03-08 | Abbott Laboratories | Quinoline antibacterial compounds |
| NZ208470A (en) * | 1983-07-18 | 1988-06-30 | Abbott Lab | 6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid derivatives and antibacterial compositions containing such |
| US4571396A (en) * | 1984-04-16 | 1986-02-18 | Warner-Lambert Company | Antibacterial agents |
| EP0191185B1 (en) * | 1984-12-14 | 1990-03-07 | Daiichi Seiyaku Co., Ltd. | Quinoline-carboxylic acid derivatives |
| IL77846A (en) * | 1985-03-25 | 1989-08-15 | Warner Lambert Co | Process for the preparation of 7-amino-quinolin-4-oxy-3-carboxylic acid derivatives |
| US4578473A (en) * | 1985-04-15 | 1986-03-25 | Warner-Lambert Company | Process for quinoline-3-carboxylic acid antibacterial agents |
| US4684648A (en) * | 1985-05-10 | 1987-08-04 | Otsuka Pharmaceutical Company Limited | Antimicrobial 1-substituted phenyl-4-oxoquinoline-3-carboxylic acid compounds and compositions thereof |
| IN166416B (zh) * | 1985-09-18 | 1990-05-05 | Pfizer | |
| US4772706A (en) * | 1986-01-13 | 1988-09-20 | Warner-Lambert Company | Process for quinoline-3-carboxylic acid antibacterial agents |
| US4840956A (en) * | 1986-02-18 | 1989-06-20 | Warner-Lambert Company | Novel disubstituted-7-pyrrolidinoquinoline antibacterial agents |
| EP0251308B1 (de) * | 1986-07-04 | 1990-11-22 | Chemie Linz Gesellschaft m.b.H. | 4-Chinolon-3-carbonsäurederivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate |
| DE3721745A1 (de) * | 1986-07-04 | 1988-01-14 | Lentia Gmbh | Bicyclisch substituierte chinoloncarbonsaeurederivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
| DE3641312A1 (de) * | 1986-12-03 | 1988-06-09 | Bayer Ag | Verfahren zur herstellung von chinolincarbonsaeuren |
| US4923879A (en) * | 1987-07-31 | 1990-05-08 | Warner-Lambert Company | 1,8-Naphthyridines and their use as antibacterial agents |
| US4851418A (en) * | 1987-08-21 | 1989-07-25 | Warner-Lambert Company | Naphthyridine antibacterial agents containing an α-amino acid in the side chain of the 7-substituent |
-
1986
- 1986-08-18 IN IN740/DEL/86A patent/IN166416B/en unknown
- 1986-08-19 US US06/898,458 patent/US4775668A/en not_active Expired - Lifetime
- 1986-08-19 US US06/898,473 patent/US4861779A/en not_active Expired - Lifetime
- 1986-08-28 MW MW58/86A patent/MW5886A1/xx unknown
- 1986-09-03 ZM ZM85/86A patent/ZM8586A1/xx unknown
- 1986-09-12 EP EP86307045A patent/EP0215650B1/en not_active Expired - Lifetime
- 1986-09-12 DE DE1996175019 patent/DE19675019I2/de active Active
- 1986-09-12 DE DE8686307045T patent/DE3683711D1/de not_active Expired - Lifetime
- 1986-09-12 AT AT86307045T patent/ATE72245T1/de active
- 1986-09-15 IL IL80033A patent/IL80033A/xx not_active IP Right Cessation
- 1986-09-15 EG EG580/86A patent/EG18184A/xx active
- 1986-09-16 PL PL1986261410A patent/PL149987B1/pl unknown
- 1986-09-16 ES ES8601935A patent/ES2001428A6/es not_active Expired
- 1986-09-16 PT PT83388A patent/PT83388B/pt unknown
- 1986-09-16 GR GR862363A patent/GR862363B/el unknown
- 1986-09-16 SK SK6678-86A patent/SK667886A3/sk unknown
- 1986-09-16 CA CA000518238A patent/CA1340734C/en not_active Expired - Lifetime
- 1986-09-16 CZ CS866678A patent/CZ277825B6/cs not_active IP Right Cessation
- 1986-09-17 MA MA20998A patent/MA20770A1/fr unknown
- 1986-09-17 DK DK445886A patent/DK171276B1/da not_active IP Right Cessation
- 1986-09-17 AU AU62768/86A patent/AU576302B2/en not_active Expired
- 1986-09-17 OA OA58953A patent/OA08410A/xx unknown
- 1986-09-17 ZW ZW193/86A patent/ZW19386A1/xx unknown
- 1986-09-17 KR KR1019860007855A patent/KR870000961B1/ko not_active IP Right Cessation
- 1986-09-17 CN CN86106385A patent/CN1014789B/zh not_active Expired
- 1986-09-17 ZA ZA867063A patent/ZA867063B/xx unknown
- 1986-09-17 MX MX003751A patent/MX173358B/es unknown
- 1986-09-17 IE IE247986A patent/IE58966B1/en not_active IP Right Cessation
- 1986-09-17 NZ NZ217614A patent/NZ217614A/xx unknown
- 1986-09-17 SU SU864028142A patent/SU1482531A3/ru active
- 1986-09-17 NO NO863718A patent/NO170335C/no not_active IP Right Cessation
- 1986-09-17 DD DD86294486A patent/DD259190A5/de unknown
- 1986-09-17 YU YU1617/86A patent/YU45024B/xx unknown
- 1986-09-17 UA UA4028142A patent/UA6340A1/uk unknown
- 1986-09-17 FI FI863756A patent/FI87565C/fi not_active IP Right Cessation
- 1986-09-17 HU HU863976A patent/HU200462B/hu unknown
- 1986-09-18 BG BG076465A patent/BG49275A3/xx active Active
- 1986-09-18 JP JP61220819A patent/JPH0798819B2/ja not_active Expired - Lifetime
- 1986-09-18 PH PH34266A patent/PH24048A/en unknown
-
1987
- 1987-08-25 MY MYPI87001447A patent/MY102518A/en unknown
-
1988
- 1988-02-16 US US07/157,182 patent/US5091383A/en not_active Expired - Fee Related
-
1989
- 1989-07-11 PH PH38922A patent/PH25338A/en unknown
-
1992
- 1992-03-17 BG BG096080A patent/BG61091B2/bg unknown
-
1994
- 1994-02-22 SG SG28094A patent/SG28094G/en unknown
-
1995
- 1995-08-24 HK HK132795A patent/HK132795A/xx not_active IP Right Cessation
- 1995-10-20 CY CY177495A patent/CY1774A/xx unknown
-
1999
- 1999-02-24 LU LU90356C patent/LU90356I2/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK667886A3 (en) | Substituted bridged diazabicycloalkylquinolonecarboxylic acids, process for producing and pharmaceutical compositions containing the same | |
| US4571396A (en) | Antibacterial agents | |
| JPH05271229A (ja) | キノロン−およびナフチリドン−カルボン酸誘導体類 | |
| CS246065B2 (en) | Method of new 7-substituted cyclic aminonaphthyridine-,quinoline-and benzoxazinecarboxylic acids production | |
| US5091384A (en) | Anti-bacterial quinolone- and naphthyridone-carboxylic acid compounds | |
| LU85871A1 (en) | 1,4-DIHYDRO-4-OXONAPHTYRIDINE DERIVATIVES AND SALTS THEREOF, PROCESS FOR THEIR PREPARATION AND ANTIBACTERIAL AGENTS CONTAINING THEM | |
| JPH0587077B2 (zh) | ||
| NO178149B (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive 7-tetrahydro-naftyridin-6-fluor-1,4-dihydro-4-okso-kinolin-3-karboksylsyrer | |
| EP0305744A2 (en) | Quinoline, naphthyridine and benzoxazine-carboxylic acid derivatives and their use as antibacterial agents | |
| SK123895A3 (en) | Derivatives of quinolone carboxylic and naphtyridone carboxylic acid, manufacturing process thereof, drugs containing same and their use | |
| US4962108A (en) | Antibacterial quinoline compounds | |
| AU668286B2 (en) | Diazabicyclo(4.3.0)nonane and (3.3.0)octane heterocycles | |
| JPH0348682A (ja) | ピリドンカルボン酸化合物 | |
| JPH08253480A (ja) | １，６−ナフチリドンカルボン酸誘導体 | |
| IE19970856A1 (en) | 7-(1-Pyrrolidinyl)-3-quinolone and naphthyridone carboxylic acid derivatives, method for their preparation and for substituted mono- and bicyclic pyrrolidine intermediates, and their antibacterial and feed additive compositions |